Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer

Journal of Urology

Volumn 193, Issue 3, 2015, Pages 807-811

  Welty, Christopher J ^a   Cowan, Janet E ^a   Nguyen, Hao ^a   Shinohara, Katsuto ^a   Perez, Nannette ^a   Greene, Kirsten L ^a   Chan, June M ^a   Meng, Maxwell V ^a   Simko, Jeffry P ^a   Cooperberg, Matthew R ^a   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biopsy; disease progression; outcome assessment; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER RISK; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; LOCAL THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NORTH AMERICA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SIZE; PROSTATE VOLUME; RETROSPECTIVE STUDY; RISK FACTOR; TRANSRECTAL ULTRASONOGRAPHY; BIOPSY; BLOOD; CLASSIFICATION; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TIME; WATCHFUL WAITING;

BIOPSY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; WATCHFUL WAITING;

EID: 84922610494     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.09.094     Document Type: Article

References (30)

1. Cancer Facts & Figures 2014 2014 American Cancer Society Atlanta 1 72
2. M.R. Cooperberg, D.P. Lubeck, and M.V. Meng The changing face of low-risk prostate cancer: trends in clinical presentation and primary management J Clin Oncol 22 2004 2141
3. P.C. Albertsen, J.A. Hanley, and J. Fine 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095
4. L.D.F. Venderbos, L.P. Bokhorst, and C.H. Bangma Active surveillance: oncologic outcome Curr Opin Urol 23 2013 268
5. L. Klotz Active surveillance: the Canadian experience Active Surveillance for Localized Prostate Cancer 2012 Humana Press Totowa 95 105
6. E.D. Selvadurai, M. Singhera, and K. Thomas Medium-term outcomes of active surveillance for localised prostate cancer Eur Urol 64 2013 981
7. R.A. Godtman, E. Holmberg, and A. Khatami Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial Eur Urol 63 2013 101
8. M.R. Cooperberg, M.R. Cooperberg, and J.M. Broering Contemporary trends in low risk prostate cancer: risk assessment and treatment J Urol 178 suppl. 2007 S14
9. L. Klotz Active surveillance for prostate cancer: for whom? J Clin Oncol 23 2005 8165
10. M.A. Dall'Era, M.R. Cooperberg, and J.M. Chan Active surveillance for early-stage prostate cancer: review of the current literature Cancer 112 2008 1650
11. M. Bul, X. Zhu, and R. Valdagni Active surveillance for low-risk prostate cancer worldwide: the PRIAS study Eur Urol 63 2013 597
12. O.N. Kryvenko, H.B. Carter, and B.J. Trock Biopsy criteria for determining appropriateness for active surveillance in the modern era Urology 83 2014 869
13. A. Lam, A. Loblaw, and R. Nam Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance J Urol 184 2010 1942
14. K.S. Tseng, P. Landis, and J.I. Epstein Risk stratification of men choosing surveillance for low risk prostate cancer J Urol 183 2010 1779
15. A.E. Ross, S. Loeb, and P. Landis Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program J Clin Oncol 28 2010 2810
16. D. Margel, I. Nandy, and T.H. Wilson Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study J Urol 190 2013 2039
17. K.C. Cary, J.E. Cowan, and M. Sanford Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies Eur Urol 66 2013 337
18. M.H. Umbehr, E.A. Platz, and S.B. Peskoe Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density BJU Int 113 2014 561
19. G.A. Barayan, F. Brimo, and L.R. Bégin Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort BJU Int 114 2014 E99
20. N.M. Corcoran, R.G. Casey, and M.K.H. Hong The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume BJU Int 110 2012 36
21. A. Vellekoop, S. Loeb, and Y. Folkvaljon Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer J Urol 191 2014 350
22. M.R. Cooperberg, D.J. Pasta, and E.P. Elkin The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy J Urol 173 2005 1938
23. Z. Gong, I. Agalliu, and D.W. Lin Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men Cancer Causes Control 19 2008 25
24. S.E. Eggener, A. Mueller, and R.K. Berglund A Multi-institutional evaluation of active surveillance for low risk prostate cancer J Urol 189 suppl. 2013 S19
25. L. Klotz, D. Vesprini, and A. Loblaw Long term follow-up of a large active surveillance cohort J Urol 191 suppl. 2014 e411 abstract PD14-03
26. J. Xia, B.J. Trock, and M.R. Cooperberg Prostate cancer mortality following active surveillance versus immediate radical prostatectomy Clin Cancer Res 18 2012 5471
27. R.C.N. van den Bergh, H.U. Ahmed, and C.H. Bangma Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review Eur Urol 65 2014 1023
28. A.W. Partin, H.B. Carter, and D.W. Chan Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia J Urol 143 1990 747
29. Y.C. Cohen, K.S. Liu, and N.L. Heyden Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial J Natl Cancer Inst 99 2007 1366
30. C.J. Welty, M.R. Cooperberg, and P.R. Carroll Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer Curr Opin Urol 24 2014 288